The illusion of prostate-specific antigen decline in patients with metabolic syndrome and insulin resistance

BJU International

Volumn 108, Issue 11, 2011, Pages 1756-1761

  Choi, Ho Chun ^a   Park, Jin Ho ^a   Cho, Be Long ^a   Son, Ki Young ^a   Yoo, Youk Jin ^a   Kwon, Hyuk Tae ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

Author keywords

insulin resistance; metabolic syndrome; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; HEMODILUTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MASS; METABOLIC SYNDROME X; PLASMA VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PLASMA VOLUME; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 81255141915     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10225.x     Document Type: Article

References (25)

1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R,. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54 (Pubitemid 40396812)
2. Huang PL,. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2: 231-7
3. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A,. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203; discussion 204-6
4. Vikram A, Jena G, Ramarao P,. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol 2010; 641: 75-81
5. Kim YJ, Cho YJ, Oh JE, Jeon YS, Lee SC, Kim WJ,. The association between metabolic syndrome and prostate-specific antigen levels. Int J Urol 2008; 15: 905-9
6. Jeong IG, Hwang SS, Kim HK, Ahn H, Kim CS,. The association of metabolic syndrome and its components with serum prostate-specific antigen levels in a Korean-screened population. Cancer Epidemiol Biomarkers Prev 2010; 19: 371-80
7. Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao G,. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev 2008; 17: 2467-72
8. Fowke JH, Matthews CM, Buchowski MS, et al,. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis 2008; 11: 264-9
9. Kaaks R, Lukanova A, Rinaldi S, et al,. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12: 309-15 (Pubitemid 36994086)
10. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT,. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23 (Pubitemid 40686299)
11. Balk SP, Ko YJ, Bubley GJ,. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-91 (Pubitemid 46606169)
12. Grubb RL III, Black A, Izmirlian G, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 748-51
13. Banez LL, Hamilton RJ, Partin AW, et al,. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-80 (Pubitemid 350146217)
14. Freedland SJ, Platz EA,. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97 (Pubitemid 47229642)
15. WHO/IASO/IOTF. The Asia-Pacific perspective: redefining obesity and its treatment. February 2000 Available at:. Accessed March 28 2011
16. Grundy SM, Cleeman JI, Daniels SR, et al,. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52 (Pubitemid 41532612)
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19 (Pubitemid 15018832)
18. Park SH, Lee WY, Rhee EJ, et al,. Relative risks of the metabolic syndrome according to the degree of insulin resistance in apparently healthy Korean adults. Clin Sci (Lond) 2005; 108: 553-9
19. Du Bois D, Du Bois EF,. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71
20. Boer P,. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 1984; 247: F632-6 (Pubitemid 15209771)
21. Oesterling JE, Jacobsen SJ, Chute CG, et al,. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4 (Pubitemid 23234116)
22. Moul S, McVary KT,. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7-12
23. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E,. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16 (Pubitemid 17147932)
24. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-84
25. 9Tc(m)-labelled DMP-HSA. Nucl Med Commun 2000; 21: 539-44